Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nkarta (NKTX – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $10.73.
Willey covers the Healthcare sector, focusing on stocks such as Exelixis, IGM Biosciences, and Nkarta. According to TipRanks, Willey has an average return of 9.2% and a 42.47% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $12.17 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $11.23 and a one-year low of $1.28. Currently, Nkarta has an average volume of 3.65M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nkarta (NKTX) Company Description:
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
Read More on NKTX:
- Nkarta presents NKX101 clinical data at 2023 ASH Annual Meeting
- Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
- Nkarta price target lowered to $9 from $15 at Mizuho
- Nkarta price target lowered to $11 from $15 at Stifel
- Nkarta reports Q3 EPS (52c), consensus (67c)
